June 29th 2020, 2:04pm
Sagar Lonial, MD, FACP, discusses the updated data from DREAMM-2 with belantamab mafodotin, associated toxicities to be aware of, and future directions for research.
June 29th 2020, 1:25pm
Noopur Raje, MD, discusses the rationale for CAR T-cell therapy in multiple myeloma.
June 29th 2020, 1:13pm
María-Victoria Mateos, MD, PhD, discusses the significance of the ongoing phase 3 CANOVA trial, which is examining venetoclax in patients with relapsed/refractory t(11;14) multiple myeloma.
June 26th 2020, 8:30pm
Caitlin Costello, MD, discusses proper dosing of carfilzomib in relapsed/refractory multiple myeloma.
June 25th 2020, 9:47pm
There was no shortage of exciting developments at the 2020 ASCO Virtual Scientific Program in multiple myeloma. Peter Voorhees, MD, explained all of the pivotal data in myeloma therapeutics in a virtual presentation during the 2020 ASCO Direct Highlights webcast.
June 25th 2020, 9:35pm
Jesus G. Berdeja, MD, discusses next steps for the phase 2 CARTITUDE-1 study with JNJ-4528 in relapsed/refractory myeloma.
June 25th 2020, 2:10pm
Saad Z. Usmani, MD, FACP, discusses current challenges in patients with high-risk multiple myeloma.
June 25th 2020, 12:50pm
The quadruplet regimen of isatuximab-irfc, carfilzomib, lenalidomide, and dexamethasone elicited a 100% overall response rate and high rates of minimal residual disease negativity in high-risk newly diagnosed multiple myeloma.
June 24th 2020, 12:52pm
Jesus G. Berdeja, MD, further discusses other exciting trials in multiple myeloma and CAR T therapy being presented at the 2020 ASCO Virtual Scientific Program.
June 23rd 2020, 1:00pm
Paul G. Richardson, MD, discusses the patient population analyzed in the first-in-human phase 1 trial of the CELMoD CC-92480.
